Skip to contentR
RenovoRx, Inc.
R
RNXTRenovoRx, Inc. Released Nov 15, 2021, after the close
10-Q filed Nov 15, 2021, 46 days after period end · 0001493152-21-028585
Q3 2021 · 10-Q
Revenue—
Net Income-$1.51M-$1.51MN/M vs Q3 2020N/M vs Q2 2021 EPS Diluted-$0.27-$0.27
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
no prior Q2 2021 on file
Operating Income-$1,395,000N/M Operating Cash Flowderived-$1,119,000— ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end
12.9% from the close of Nov 15, 2021 to the close of Nov 16, 2021, the first after the release.
after the close$8.06$7.02 Oct 7Nov 15Dec 28